MaxCyte, Inc. Dr Richard Douglas Joins MaxCyte Board (6464E)
13 February 2018 - 6:00PM
UK Regulatory
TIDMMXCT TIDMMXCR
RNS Number : 6464E
MaxCyte, Inc.
13 February 2018
MaxCyte, Inc.
("MaxCyte" or the "Company")
Dr Richard Douglas Joins MaxCyte Board
Dr Douglas previously served as Senior Vice President of
Corporate Development at Genzyme
Gaithersburg, Maryland - 13 February 2018: MaxCyte (LSE: MXCT,
MXCR), the global cell-based medicines and technology company,
announces that 30-year life sciences industry veteran Richard
Douglas, Ph.D., has been appointed to the Company's Board of
Directors as an Independent Non-Executive Director.
Dr Douglas formerly served as the Senior Vice President of
Corporate Development and Corporate Officer at Genzyme Corporation
from 1989 until Genzyme was acquired by Sanofi in 2011. During this
period, Dr Douglas led numerous acquisitions, licenses, financings,
joint ventures, and strategic alliances. He had previously served
in science and corporate development capacities at Integrated
Genetics prior to its acquisition by Genzyme. He currently serves
as an Advisor to RedSky Partners, a Biotechnology-focused advisory
firm.
Dr Douglas received a Ph.D. in Biochemistry from the University
of California, Berkeley, and was a Post-Doctoral Fellow at
California Institute of Technology in Leroy Hood's laboratory. He
has a degree in Chemistry from the University of Michigan, where he
now serves as chair of the National Advisory Board for the Office
of Technology Transfer and also on two translational research
oversight committees for the University's Medical School.
"Richard's wealth of expertise in business and corporate
development and his deep life sciences industry experience will
bring invaluable perspective to the MaxCyte Board," said MaxCyte
President & CEO Doug Doerfler. "We are extremely pleased to
have Richard as part of our organisation as we further our
enablement of new medicines in the areas of gene editing and
immuno-oncology, and move our first product candidate from our
CARMA therapeutic platform into the clinic."
"I have followed MaxCyte's progress closely over the previous
years and I believe its technology is truly revolutionary," said Dr
Douglas. "With the first CARMA therapy due to enter the clinic
later this year, I am delighted to join MaxCyte at this exciting
time in its development. I look forward to working closely with the
Board and management team in bringing the next generation of
treatments to patients."
Dr Richard Huntington Douglas (age 65) is, or has been in the
previous five years, a director or partner of the following
companies:
Current appointments Past appointments
Aldeyra Therapeutics, None
Inc. (Chairman)
Novavax, Inc.
Dr Douglas does not have an interest in any common stock of
MaxCyte.
The Company confirms that there is no further information to be
disclosed pursuant to Rule 17 or Schedule Two paragraph (g) of the
AIM Rules for Companies.
About MaxCyte
MaxCyte (LSE: MXCT, MXCR) is a US-based global company driving
the acceleration of the discovery, development, manufacturing and
commercialization of next-generation, cell-based medicines. The
Company provides its patented, high-performance cell engineering
enabling technology to biopharmaceutical partners engaged in drug
discovery and development, biomanufacturing, and cell therapy,
including gene editing and immuno-oncology. With its robust
delivery technology, MaxCyte's team of scientific experts helps its
partners to unlock their product potential and solve problems. This
technology allows for the engineering of nearly all cell types,
including human primary cells, with any molecule, at any scale. It
also provides a high degree of consistency and minimal cell
disturbance, thereby facilitating rapid, large-scale, clinical and
commercial grade cell engineering in a non-viral system and with
low-toxicity concerns. The Company's cell-engineering enabling
technology is FDA-accredited, providing MaxCyte's customers and
partners with an established regulatory path to commercialize
cell-based medicines. MaxCyte is also developing CARMA, its
proprietary, breakthrough platform in immuno-oncology, to rapidly
manufacture CAR therapies for a broad range of cancer indications,
including solid
tumours where existing CAR-T approaches face significant challenges. For more information, visit http://www.maxcyte.com/.
###
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive
Officer
Ron Holtz, Chief Financial
Officer +1 301 944 1660
Nominated Adviser and Broker
Panmure Gordon
Freddy Crossley (Corporate
Finance)
Ryan McCarthy
Tom Salvesen (Corporate Broking) +44 (0) 20 7886 2500
Financial PR Adviser
Consilium Strategic Communications
Mary-Jane Elliott +44 (0)203 709 5700
Chris Welsh maxcyte@consilium-comms.com
Suki Virji
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCUUUBRWAAUAAR
(END) Dow Jones Newswires
February 13, 2018 02:00 ET (07:00 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Apr 2024 to May 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From May 2023 to May 2024